SCHEMBL4257440

SCHEMBL4257440

Cc1ccc(NC(=O)c2cccc(C)c2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.81
RAB9A P51151 5/20 0.81
TP53 P04637 4/20 0.81
KCNK3 O14649 6/20 0.77
KCNK9 Q9NPC2 5/20 0.77
KCNH2 Q12809 1/20 0.77
NT5E P21589 1/20 0.73
KMT2A Q03164 7/20 0.72
MEN1 O00255 6/20 0.72
RXFP1 Q9HBX9 1/20 0.72
SMN1; SMN2 Q16637 3/20 0.71
MAPT P10636 1/20 0.71
POLB P06746 1/20 0.71
FFAR1 O14842 1/20 0.70
GLA P06280 1/20 0.70
KDM4E B2RXH2 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
TSHR P16473 1/20 0.69
NFKB1 P19838 1/20 0.69
NFKB2 Q00653 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30048093 1.00 NPC1 (0.81) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL5380687 0.90 TP53 (1.00) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL30555199 0.90 TP53 (1.00) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL30608967 0.89 KCNK3 (0.87) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL259666 0.89 KCNK3 (0.87) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL16675166 0.89 KCNK3 (0.89) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL12259119 0.88 TP53 (0.78) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL7822889 0.88 MEN1 (0.78) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL14531871 0.88 TP53 (0.74) NPC1RAB9ATP53KCNK3KCNK9
SCHEMBL677855 0.88 TP53 (0.74) NPC1RAB9ATP53KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115304507-A Synthesis method of N-substituted aryl formamide 兰州石化职业技术大学 2022-11-08 CN disclosed
EP-3187490-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-07-05 EP disclosed
EP-1773786-B1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-04-26 EP disclosed
US-9321766-B1 Kinase inhibitors ALLERGAN, INC. (US) 2016-04-26 US disclosed
US-20160096832-A1 KINASE INHIBITORS ALLERGAN, INC. 2016-04-07 US disclosed
US-20160082699-A1 RESIN LAYER-ATTACHED SUPPORTING SUBSTRATE AND METHOD FOR PRODUCING SAME, GLASS LAMINATE AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ELECTRONIC DEVICE ASAHI GLASS COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160082699-A1 RESIN LAYER-ATTACHED SUPPORTING SUBSTRATE AND METHOD FOR PRODUCING SAME, GLASS LAMINATE AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ELECTRONIC DEVICE ASAHI GLASS COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160075110-A1 FLEXIBLE SUBSTRATE AND METHOD FOR PRODUCING SAME, GLASS LAMINATE AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ELECTRONIC DEVICE ASAHI GLASS COMPANY, LIMITED (JP) 2016-03-17 US disclosed
US-8357210-B2 Disazo acid dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2013-01-22 US disclosed
EP-2027213-B1 DISAZO ACID DYES CLARIANT FINANCE BVI LTD (VG) 2012-11-21 EP disclosed
US-7754196-B2 Cosmetic composition comprising fiber L'OREAL (FR) 2010-07-13 US disclosed
US-20090126128-A1 Disazo Acid Dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2009-05-21 US disclosed
US-20090126128-A1 Disazo Acid Dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2009-05-21 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-7157548-B2 Crosslinked sulfonated polyimide films HANYANG HAK WON CO., LTD. (KR) 2007-01-02 US disclosed
US-7157548-B2 Crosslinked sulfonated polyimide films HANYANG HAK WON CO., LTD. (KR) 2007-01-02 US disclosed
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 NPC1 869/4885RAB9A 733/4885TP53 4869/4885
US-20160096832-A1 KINASE INHIBITORS ABL1, LCK, ERBB2 NPC1 4204/4885RAB9A 2799/4885TP53 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.